|
1
|
Brisdelli F, D’Andrea G and Bozzi A:
Resveratrol: A natural polyphenol with multiple chemopreventive
properties. Curr Drug Metab. 10:530–546. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fauconneau B, Waffo-Teguo P, Huguet F,
Barrier L, Decendit A and Merillon JM: Comparative study of radical
scavenger and antioxidant properties of phenolic compounds from
Vitis vinifera cell cultures using in vitro tests. Life Sci.
61:2103–2110. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim AL, Zhu Y, Zhu H, Han L, Kopelovich L,
Bickers DR and Athar M: Resveratrol inhibits proliferation of human
epidermoid carcinoma A431 cells by modulating MEK1 and AP-1
signalling pathways. Exp Dermatol. 15:538–546. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Baur JA and Sinclair DA: Therapeutic
potential of resveratrol: The in vivo evidence. Nat Rev Drug
Discov. 5:493–506. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shankar S, Singh G and Srivastava RK:
Chemoprevention by resveratrol: Molecular mechanisms and
therapeutic potential. Front Biosci. 12:4839–4854. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Alao JP: The regulation of cyclin D1
degradation: Roles in cancer development and the potential for
therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aggarwal BB, Bhardwaj A, Aggarwal RS,
Seeram NP, Shishodia S and Takada Y: Role of resveratrol in
prevention and therapy of cancer: Preclinical and clinical studies.
Anticancer Res. 24:2783–2840. 2004.PubMed/NCBI
|
|
8
|
Bhardwaj A, Sethi G, Vadhan-Raj S,
Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S and Aggarwal
BB: Resveratrol inhibits proliferation, induces apoptosis, and
overcomes chemoresistance through down-regulation of STAT3 and
nuclear factor-kappaB-regulated antiapoptotic and cell survival
gene products in human multiple myeloma cells. Blood.
109:2293–2302. 2007. View Article : Google Scholar
|
|
9
|
Shimizu T, Nakazato T, Xian MJ, Sagawa M,
Ikeda Y and Kizaki M: Resveratrol induces apoptosis of human
malignant B cells by activation of caspase-3 and p38 MAP kinase
pathways. Biochem Pharmacol. 71:742–750. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de la Lastra CA and Villegas I:
Resveratrol as an anti-inflammatory and anti-aging agent:
Mechanisms and clinical implications. Mol Nutr Food Res.
49:405–430. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Park JH, Min HY, Kim SS, Lee JY, Lee SK
and Lee YS: Styrylquinazolines: A new class of inhibitors on
prostaglandin E2 production in
lipopolysaccharide-activated macrophage cells. Arch Pharm.
337:20–24. 2004. View Article : Google Scholar
|
|
12
|
Molinari M: Cell cycle checkpoints and
their inactivation in human cancer. Cell Prolif. 33:261–274. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taylor WR and Stark GR: Regulation of the
G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harvey SL, Charlet A, Haas W, Gygi SP and
Kellogg DR: Cdk1-dependent regulation of the mitotic inhibitor
Wee1. Cell. 122:407–420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Senderowicz AM and Sausville EA:
Preclinical and clinical development of cyclin-dependent kinase
modulators. J Natl Cancer Inst. 92:376–387. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou BB and Bartek J: Targeting the
checkpoint kinases: Chemosensitization versus chemoprotection. Nat
Rev Cancer. 4:216–225. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartek J and Lukas J: Chk1 and Chk2
kinases in checkpoint control and cancer. Cancer Cell. 3:421–429.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ahn J, Urist M and Prives C: Questioning
the role of checkpoint kinase 2 in the p53 DNA damage response. J
Biol Chem. 278:20480–20489. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vousden KH and Lu X: Live or let die: The
cell’s response to p53. Nat Rev Cancer. 2:594–604. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu S, Bishop WR and Liu M: Differential
effects of cell cycle regulatory protein p21WAF1/Cip1 on
apoptosis and sensitivity to cancer chemotherapy. Drug Resist
Updat. 6:183–195. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kinner A, Wu W, Staudt C and Iliakis G:
Gamma-H2AX in recognition and signaling of DNA double-strand breaks
in the context of chromatin. Nucleic Acids Res. 36:5678–5694. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Matsuoka S, Huang M and Elledge SJ:
Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.
Science. 282:1893–1897. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Signorelli P and Ghidoni R: Resveratrol as
an anticancer nutrient: Molecular basis, open questions and
promises. J Nutr Biochem. 16:449–466. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Das DK, Sato M, Ray PS, Maulik G, Engelman
RM, Bertelli AA and Bertelli A: Cardioprotection of red wine: Role
of polyphenolic antioxidants. Drugs Exp Clin Res. 25:115–120.
1999.PubMed/NCBI
|
|
25
|
Nawroth R, Poell G, Ranft A, Kloep S,
Samulowitz U, Fachinger G, Golding M, Shima DT, Deutsch U and
Vestweber D: VE-PTP and VE-cadherin ectodomains interact to
facilitate regulation of phosphorylation and cell contacts. EMBO J.
21:4885–4895. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahmad N, Adhami VM, Afaq F, Feyes DK and
Mukhtar H: Resveratrol causes WAF-1/p21-mediated
G1-phase arrest of cell cycle and induction of apoptosis
in human epidermoid carcinoma A431 cells. Clin Cancer Res.
7:1466–1473. 2001.PubMed/NCBI
|
|
27
|
Zhang P, Li H, Wu ML, Chen XY, Kong QY,
Wang XW, Sun Y, Wen S and Liu J: c-Myc downregulation: A critical
molecular event in resveratrol-induced cell cycle arrest and
apoptosis of human medulloblastoma cells. J Neurooncol. 80:123–131.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou BB and Elledge SJ: The DNA damage
response: Putting checkpoints in perspective. Nature. 408:433–439.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Peng CY, Graves PR, Thoma RS, Wu Z, Shaw
AS and Piwnica-Worms H: Mitotic and G2 checkpoint control:
Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C
on serine-216. Science. 277:1501–1505. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Reinhardt HC and Yaffe MB: Kinases that
control the cell cycle in response to DNA damage: Chk1, Chk2, and
MK2. Curr Opin Cell Biol. 21:245–255. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shiloh Y: ATM and related protein kinases:
Safeguarding genome integrity. Nat Rev Cancer. 3:155–168. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu J and Zhang L: The transcriptional
targets of p53 in apoptosis control. Biochem Biophys Res Commun.
331:851–858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: Role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
34
|
Athar M, Back JH, Tang X, Kim KH,
Kopelovich L, Bickers DR and Kim AL: Resveratrol: A review of
preclinical studies for human cancer prevention. Toxicol Appl
Pharmacol. 224:274–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tay WM, da Silva GF and Ming LJ: Metal
binding of flavonoids and their distinct inhibition mechanisms
toward the oxidation activity of Cu2+-β-amyloid: Not
just serving as suicide antioxidants! Inorg Chem. 52:679–690. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mansilla S, Bataller M and Portugal J:
Mitotic catastrophe as a consequence of chemotherapy. Anticancer
Agents Med Chem. 6:589–602. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sahu RP, Batra S and Srivastava SK:
Activation of ATM/Chk1 by curcumin causes cell cycle arrest and
apoptosis in human pancreatic cancer cells. Br J Cancer.
100:1425–1433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Goel A, Kunnumakkara AB and Aggarwal BB:
Curcumin as ‘Curecumin’: From kitchen to clinic. Biochem Pharmacol.
75:787–809. 2008. View Article : Google Scholar
|
|
39
|
van Vugt MA and Medema RH: Getting in and
out of mitosis with Polo-like kinase-1. Oncogene. 24:2844–2859.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Iliakis G, Wang Y, Guan J and Wang H: DNA
damage checkpoint control in cells exposed to ionizing radiation.
Oncogene. 22:5834–5847. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang J, Yu Y, Hamrick HE and
Duerksen-Hughes PJ: ATM, ATR and DNA-PK: Initiators of the cellular
genotoxic stress responses. Carcinogenesis. 24:1571–1580. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shieh SY, Ahn J, Tamai K, Taya Y and
Prives C: The human homologs of checkpoint kinases Chk1 and Cds1
(Chk2) phosphorylate p53 at multiple DNA damage-inducible sites.
Genes Dev. 14:289–300. 2000.PubMed/NCBI
|
|
43
|
Zeng Y, Forbes KC, Wu Z, Moreno S,
Piwnica-Worms H and Enoch T: Replication checkpoint requires
phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature.
395:507–510. 1998. View
Article : Google Scholar : PubMed/NCBI
|
